Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety & Efficacy of Prolonged Physiologic Erythropoietin (EPO) Level Treatment of Anemia in End Stage Renal Disease (ESRD) Patients Undergoing Peritoneal Dialysis (PD)Using MDGN201 TARGTEPO

NCT02378662 is registered in ClinicalTrials.gov with Aevi Genomic Medicine, LLC, a Cerecor company as lead sponsor.

NCT NCT02378662
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02378662 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety & Efficacy of Prolonged Physiologic Erythropoietin (EPO) Level Treatment of Anemia in End Stage Renal Disease (ESRD) Patients Undergoing Peritoneal Dialysis (PD)Using MDGN201 TARGTEPO
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Phase
Phase 2
Overall status
Terminated
Start date
April 30, 2015
Completion date
June 30, 2016
Enrollment
2 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

anemia of end stage renal disease